AstraZeneca is planting its flag in the oral SERD space, touting positive Phase 3 breast cancer data for a program it expects ...

Checkpoint therapies like Keytruda, Opdivo, and Imfinzi are expanding from late-stage to early-stage cancer treatment, with ...

Novo Nordisk warned the US government not to impose pharma-specific tariffs, but instead to tax illegal importers of ...

The CDC will no longer recommend routine Covid-19 vaccines for healthy kids and pregnant women after HHS Secretary Robert F.

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

As of Thursday morning, just over 300 entries out of at least 950 public comments have been released by the Department of ...

Strand Therapeutics reports early positive data for STX-001, a self-replicating mRNA cancer therapy, showing safety and ...

Prothena abandons birtamimab after Phase 3 amyloidosis trial failure, plans layoffs. Drug previously failed mid-stage trial.

The companies said Thursday that they voluntarily withdrew the accelerated approval request for patritumab deruxtecan in ...

Indy biotech Syndeio launches with $90M, led by CEO Derek Small, to develop NMDA receptor drugs for depression & Alzheimer's, ...

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a ...

Protein degrader shop GlycoEra, spun out of vaccines company LimmaTech in 2021, has corralled $130 million in Series B ...